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Abstract 
Purpose: To formulate solid lipid microparticles (SLM) of loratadine (LRT) for the treatment of allergic 
reactions via the nasal route. 
Methods: Microparticles were prepared by emulsion congealing technique. The drug content of 
microparticles was analysed. Drug/excipient compatibility and crystallinity characteristics of 
microparticles were investigated by Fourier Transform Infrared Spectroscopy (FT-IR) and differential 
scanning calorimetry (DSC). Particle size distribution was determined by laser diffraction (LD). Drug 
release from microparticles was compared to that from conventional vehicles (O/W emulsion, gel and 
oleageneous cream) using Franz-type diffusion cells.  
Results: Drug content of microparticles was > 87.96 %. FT-IR and DSC analysis indicated that the drug 
and excipients were compatible for at least 6 months at room temperature after production. 
Microparticle size was between 86 ± 5.63 µm and 184 ± 13.21 µm while mean droplet size of O/W 
emulsion was 76 ± 3.45 µm. Release profiles of LRT from microparticles were significantly different from 
those of O/W emulsion, gel and oleageneous cream (p < 0.05). In the case of conventional vehicles, 
increase in the hydrophilicity of the vehicles led to increase in drug release rate. Drug release fitted 
generally to zero order kinetics as well as Korsmeyer-Peppas model for one of the SLM formulations, 
indicating non-Fickian drug release (super case II transport).  
Conclusion: SLM provided LRT release for a longer period than the conventional vehicles. However, in 
vivo studies are required to ascertain the effectiveness of the formulations. 
 
Keywords: Loratadine, Solid lipid microparticles, Allergy, Controlled drug delivery, Transnasal delivery 
 
Tropical Journal  of Pharmaceutical Research is ind exed by Science Citation Index (SciSearch), Scopus,  
International Pharmaceutical Abstract, Chemical Abs tracts, Embase, Index Copernicus, EBSCO, African 
Index Medicus, JournalSeek, Journal Citation Report s/Science Edition, Directory of Open Access Journal s 




Loratadine (LRT) is a selective peripheral 
histamine H1-receptor antagonist. It is commonly 
used for the treatment of chronic idiopathic 
urticaria, allergic rhinitis and asthma by the oral 
route. Its pharmacological activity is based on 
inhibition of histamine release from the basophilic 
granulocytes and the mastocytes where 
histamine is stored in tissues [1,2]. At the same 
time, histamine release continues for days as 
soon as allergic reactions start. This situation 
significantly affects actual life of patients 
particularly in case of respiratory and skin 
reactions like asthma, rhinitis and urticaria. 
Topical application of LRT could be an 
alternative to oral administration. Thus, topical 
applications of LRT including nasal [3], 
ophthalmic [1] and skin [4] have been reported 
for the treatment of allergic rhinitis, asthma and 
various allergic illnesses in the last few years.  
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Incorporation of LRT into microparticles is one of 
the approaches used to provide sustained drug 
delivery. Nasal application of microparticles 
containing LRT will introduce both rapid 
management of allergic reactions and 
subsequent prolonged drug delivery. Thus, 
excessive histamine release from granulocytes 
and mastocytes during can be brought under 
control and/or prevented. Furthermore, systemic 
side effects of drugs reported via oral 
administration can be minimized/eliminated with 
controlled drug delivery by nasal administration 
of microparticles [5]. Microparticular carrier 
systems of LRT may also be used for efficient 
controlled release inhalation therapy in allergic 
respiratory reactions [6,7].  
 
The objective of this preliminary study was to 
formulate SLM of LRT and compare its 
physicochemical properties, including drug 
release, with those of conventional vehicles (O/W 
emulsion, gel and oleageneous cream), for 
possible nasal administration.  
 




Loratadine (LRT) was kindly provided by Teva 
Pharmaceutical Works Private Ltd (Hungary). 
Glyceryl tristearate, Pluronic® F68, oleic acid, 
Tween® 80 and propylene glycol were purchased 
from Sigma-Aldrich Inc (Turkey). Precirol® ATO 5 
(Gattefossé, France) was generously supplied by 
B’IOTA Laboratories (Turkey). Carbopol® 934 
was kindly provided by Lubrizol Corp. (USA). All 
the other chemicals were of analytical grade. 
 
Preparation of formulations   
 
SLM was produced by emulsion congealing 
technique at a temperature at least 15 oC higher 
than the melting point of the solid lipid (Table 1) 
[8]. Lipophilic phase was melted and the drug 
was added to the lipid melt. A hot aqueous 
surfactant solution was added. The mixture was 
homogenized using an Ultra-Turrax T25 
homogenizer (Jahnke und Kunkel GmbH, 
Germany) at 20 000 rpm for 20 min. The hot 
emulsion obtained was kept under the water 
flowing from a tap for crystallization of the lipid. 
SLM was obtained by filtration of the dispersion 
through S&S5893 blue ribbon paper (2 µm pore 
size, Schleicher & Schuell, Germany), dried in 
open air overnight and then transferred to a 
desiccator containing calcium chloride as the 
desiccant to keep for 2 days. DSC, FT-IR, LD 
and study on determination of drug content in 
microparticles were performed on one part of 
SLM which was preserved in a tightly closed 
glass bottle. The other part of SLM was 
incorporated into a carbomer gel by stirring with 
a WiseStir HS-100D propeller mixer (Daihan 
Scientific Co Ltd, Korea) at 50 rpm pending its 
use for in vitro drug release studies.    
 
An O/W emulsion, gel and an oleageneous 
cream were also prepared for comparison (Table 
1). To prepare the o/w emulsion, drug was added 
to the liquid oil and the mixture heated to 85 oC. 
Hot surfactant solution at the same temperature 
was added to the mixture using the Ultra-Turrax 
T25 homogenizer. Oleageneous cream was 
prepared by incorporation of LRT into the 
lipid/propylene glycol mixture at 85 oC. Gel 
formulation was obtained by addition of LRT to 
the proper amount of carbomer hydrogel using a 
propeller mixer at 100 rpm and room 
temperature. 
 
Solubility of drug in the release medium 
 
Phosphate buffer (PBS, pH 7.4) and propylene 
glycol mixture (60:40) was used as the receptor 
phase for in vitro release studies. A linear curve 
was obtained between 2 and 12 µg/ml 
PBS/propylene glycol mixture (60:40) 
spectrophotometrically (Shimadzu UV-1601, 
Japan) at 249 nm in six replicates (r = 0.9994).  
 
 
Table 1:  Composition (%) of the formulations 
 
Formulation SLM1 SLM2  SLM3 SLM4 O/W emulsion Gel Oleageneous cream 
LRT 2 2 2 2 2 2 2 
Glyceryl tristearate 18 12 - - - - - 
Precirol® ATO5 - - 18 12 - - - 
Oleic acid - 6 - 6 18 - - 
Pluronic® F68 - - 2 2 2 - - 
Tween® 80 2 2 - - - - - 
Vaseline - - - - - - 83 
Carbomer 3 3 3 3 3 3 - 
Propylene glycol 15 15 15 15 15 15 15 
Water 60 60 60 60 60 80 - 
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The solubility of LRT in the receptor phase was 
studied by the method reported in USP XIX. 
PBS/propylene glycol (15 ml, 60:40) mixture was 
placed in four 25-ml flasks. Excess amount of 
LRT was placed in each flask and the flasks 
were closed tightly. All the flasks were placed in 
a constant temperature water bath at 25 ± 1 oC. 
The apparatus was maintained under 200 rpm 
continuous agitation for 24 h and the dispersion 
was then filtered through blue ribbon filter paper 
(S&S5893). A measured portion of the clear 
supernatant was removed using a pipet and 
diluted. The solubility of LRT in the receptor 
phase was determined at 249 nm. 
 
Drug content of microparticles 
 
Appropriate amount of SLM in 100 ml 
PBS/propylene glycol (60:40) was placed in an 
ultrasonic bath at 85 oC to liberate LRT from SLM 
[9]. After cooling to room temperature, it was 
filtered through S&S5893 blue ribbon filter paper. 
The supernatant (1 ml) was taken into a 10 ml 
volumetric flask and the volume made up to mark 
with PBS/propylene glycol (60:40). The amount 
of LRT in the solution was analysed 
spectrophotometrically at 249 nm. Analysis was 




Determination of interaction between LRT and 
the other ingredients of SLM formulations after 6 
months of storage at room temperature in the 
dark was investigated by FT-IR [10]. Samples 
were separately scanned over a wave number 
range of 4000  to 650 cm-1 at a resolution of 4 
cm-1 in a Perkin Elmer 100 FT-IR instrument 
(UK) equipped with Perkin Elmer Spectrum 
Version 6.0.2 Software. The system was 
adjusted to the transmission mode. The sample 
was placed on the sample stage and 100 N force 
was applied for scanning.  
 
DSC analysis  
 
DSC analysis was applied to the drug (LRT), 
pure lipid and SLM in order to investigate the 
crystalline behaviour of the lipid drug and drug-
lipid blend [11]. Samples (4 - 5 mg) were sealed 
in standard aluminium pans of the apparatus 
(DSC 204 F1 Phoenix®, Netzsch, Germany) and 
heated from 20 to 170 oC at a heating rate of 10 
K/min under a nitrogen flow rate of 20 ml/min. 
Melting peaks and enthalpies were calculated 
using the DSC 204 F1 software. The crystalline 
state of the drug and the lipid in the formulations 
was determined as the crystallinity index (% CI) 
using Eq 1 [11] 
 
CI (%) = {mesample/(mebulk x Cbulk)}100 ............. (1) 
 
where mesample = melting enthalpy of sample 
(J/g), mebulk = melting enthalpy of pure drug or 
bulk solid lipid (J/g), and Cbulk = concentration of 
the drug or solid lipid (%) 
 
Particle size measurement  
 
Particle and droplet size distributions of SLM 
formulations and O/W emulsion were determined 
using a LD instrument equipped with Hydro 
2000MU wet sample dispersion unit (Malvern 
Mastersizer Instrument, UK) [12]. Samples were 
dispersed in a certain amount of water using the 
propeller mixer at 50 rpm before the 
measurements. Measurements were performed 
in triplicate. Measurement medium was water 
with a refractive index of 1.33. Particle and 
droplet size of the formulations were analysed as 
volumetric distribution (D10, D50 and D90).  
 
In vitro drug release studies    
 
Plain gel as well as gels containing SLM and 
O/W emulsion were used for this study. The 
samples (1 g) were placed in the donor phase 
over nitrocellulose membrane (0.45 µm pore 
size, Millipore, Turkey) placed between the two 
halves of Franz-types diffusion cell with 3.15 cm2 
surface area and 33.2 ml receptor volume 
(Çalışkan Cam Teknik, Turkey) [10]. The 
receptor phase was PBS/ propylene glycol (pH 
7.4, 60:40) at 37 ± 0.5 oC, and 50 rpm rotation 
was applied to the receptor phase using 
magnetic stirrer. The test was carried out under 
sink conditions for 8 h. Samples (1 ml) were 
collected at predetermined time intervals and 
cumulative amount of drug released was 
determined spectrophotometrically (Shimadzu 
UV-1601, Japan) at 249 nm after proper dilution. 
The cumulative amount of LRT in the release 
medium was plotted as a function of time. 
Release profiles were kinetically evaluated by 
using different models (zero order, first order, 
and Higuchi square-root, Hixson-Crowell models 





In vitro drug release data were evaluated using 
GraphPad Prism software and one-way ANOVA 
to determine differences between release profiles 
at 0.05 as the level of significance. 
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Table 2:  Kinetic models used for the evaluation 
of drug release from formulations 
 
Kinetic models  
Zero order Qt = Q0 + k0t 








1/3 = κt    
Korsmeyer-
Peppas 
Log[Qt/Q∞] = logk 
+ nlogt 
Qt and Q0, amounts of drug released at time, t, and in the 
release medium at t = 0, respectively; k0, k1 and kH release 
constants of the zero order, the first order and Higuchi 
square-root models, respectively; W0 and Wt , initial and 
remaining amounts (at time t) of drug in the formulation, 
respectively; κ, constant incorporating the surface-volume 
relation; Qt/Q∞, fractional release of drug; k and n, kinetic 





Solubility of drug in the release medium 
 
The solubility of LRT was 1.152 ± 0.112 mg/mL 
in PBS/propylene glycol (60:40) mixture which 
was the receptor medium in the in vitro release 
studies.  
 
Drug content of microparticles 
 
LRT entrapped by SLM1, SLM2, SLM3 and 
SLM4 was 87.96 ± 0.019, 95.74 ± 0.008, 88.49 ± 
0.011 and 95.51 ± 0.005 %, respectively.  
 
Physicochemical properties of microparticles 
 
FT-IR profiles were obtained for pure LRT as well 
as samples of SLM2 and SLM4 containing solid 
and liquid lipid mixture (Fig 1). The pure drug 
spectrum showed the characteristic C=O 
stretching band at 1700 cm-1, C=N stretching 
band at 1643 cm-1, C=C stretching vibrations of 
benzene ring at 1560 cm−1 - 1434 cm−1, N–C 
stretching band at 1385 cm−1, C–O stretching 
bands at 1222 cm−1 and 997 cm−1, =C–H 
stretching band at 863 cm−1 and C–Cl stretching 
band at 763 cm−1. In the spectra of SLM2 and 
SLM4, the main characteristic bands of LRT 
occurred as broader peaks of lower intensity 
caused by the other ingredients. C-H, N-H and 
O-H stretching bands for lipids occured at 2956 - 
2849 cm-1. C=O carbonyl stretching band for 
lipids was detected at 1741 cm-1 and 1730 cm-1 
for SLM2 and SLM4, respectively.   
 
In DSC analysis, LRT gave a melting peak at 
137.54oC with 74.52 J/g melting enthalpy (Fig 2). 
These values were decreased by incorporation of 
drug into microparticles (Table 3). Fig 2 and 
Table 3 also introduce DSC profiles and thermal 
data of microparticles after 6 months of storage 
at room temperature.  
 
 
Figure 1:  FTIR profiles of SLM2 and SLM4 after 6 




Figure 2: DSC profiles of pure drug (LRT), pure solid 
lipids and microparticles (SLM1-SLM4) after 6 months 
of storage at room temperature 
 
Particle and droplet size distribution of SLM and 
O/W emulsion was displayed in Fig 3. SLM 
containing liquid lipid displayed lower particle 
size than the formulations that did not contain 
liquid oil. The mean particle size of SLM4 
(formulated with Precirol® ATO5) was 86 ± 5.57 
µm while the particle size of SLM2 (prepared 
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Table 3:  DSC parameters of pure drug (LRT), bulk solid lipids and microparticles (SLM1 - SLM4) 
 
Formulation 
Enthalpy  ( ∆H, J/g) Melting point ( oC) CI (%) 
 Drug Lipid Drug Lipid Drug Lipid 
Pure LRT 74.52 - 137.54 - 100 - 
Bulk glyceryl tristerate - 160.49 - 63.29 - 100 
Bulk Precirol® ATO5 - 206.04 - 68.17 - 100 
SLM1 37.31 137.17 133.12 63.80 37.31 94.97 
SLM2 25.55 86.71 131.99 61.11 25.55 90.05 
SLM3 42.58 137.55 134.58 68.11 42.58 95.23 
SLM4 27.70 110.54 132.24 63.80 27.70 89.42 
























Figure 3:  Particle and droplet size distribution of 
SLM and o/w emulsion. Bars represent D10 (□), 
D50 (■) and D90 (■) values of formulations.  




Figure 4:  Drug release from formulations; ♦ = SLM1, ■ 
= SLM2, ▲ = SLM3, ● = SLM4, ◊ = O/W, □ = Gel, ∆ = 
OC; ‘ns’ and p < 0.05 indicate non-significant and 
significant differences, respectively.  
 
In vitro drug release  
 
The solubility of LRT in the release medium 
(1.152 ± 0.112 mg/ml) indicate that drug release 
occurred under the sink conditions. The highest 
release was occurred from gel followed by O/W  
emulsion, oleageneous cream and SLM 
formulations (p < 0.05), as shown in Fig 4. 
However, insignificant difference was determined 
for drug release from formulations SLM2, SLM3 
and SLM4 (p > 0.05) while SLM1 was only 
statistically similar with SLM2 (p>0.05). 
 
Analysis of regression on cumulative percentage 
of drug release versus time curves shows high 
linearity for zero order kinetic model for the 
formulations except SLM3 which displayed 




Drug entrapment efficiency of microparticles was 
high because lipophilic materials usually 
introduce suitable matrix structures to entrap 
lipophilic drugs. Moreover, addition of liquid lipid 
into microparticles (SLM2 and SLM4) enhanced 
percent of drug entrapped since the destruction 
of crystal order and the resulting amorphous 
regions in the structure of the matrix provided 
spaces for drug to be accommodated in the 
microparticles [15]. 
 
FT-IR profiles of microparticles indicated that 
there was a physical interaction between drug 
and matrix structure of microparticles. Typical 
peaks of LRT in the fingerprint area were 
detected as broader peaks in the same 
waverange. This also indicates suitability of 
lipophilic matrix structure comprised of glyceryl 
tristearate, Precirol® ATO5 and oleic acid for 
LRT.  
 
DSC profiles displayed a prominent re-
crystallization behavior of solid lipids. Re-
crystallization of solid lipids progressed up to a 
high crystal order during 6 months of storage. 
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However, oil incorporation resulted in decrease in melting points and enthalpies with broader  
Table 4: Drug release rate and kinetic drug release data for the formulations 
 
Form.  Release rate Zero order  First order  Higuchi Hixson-Crowell Korsmeyer-Peppas  
 (mcg/cm 2/h) r r r r r (n) 
SLM1 12.35 0.9953 0.8818 0.9775 0.9903 0.9862 (1.506) 
SLM2 19.96 0.9973 0.9325 0.9747 0.9922 0.9949 (1.256) 
SLM3 22.97 0.9940 0.8893 0.9973 0.9891 0.9913 (1.078) 
SLM4 27.61 0.9954 0.9120 0.9933 0.9907 0.9936 (1.174) 
O/W 94.38 0.9988 0.9231 0.9797 0.9936 0.9986 (1.257) 
Gel 154.65 0.9973 0.9478 0.9756 0.9919 0.9984 (1.177) 
OC 50.40 0.9965 0.9347 0.9711 0.9912 0.9978 (1.222) 
r = correlation coefficient; n = diffusion exponent of release profile (slope). Best fits were bolded. 
 
melting peaks indicating delayed crystallization 
process of solid lipids. Lower re-crystallization 
rate of drug was caused by homogeneous 
distribution of drug through microparticles. Liquid 
lipid addition also resulted in a decrease in drug 
re-crystallization more.  
 
Particle size distribution of microparticles was 
homogeneous. Microparticles containing liquid 
lipid (SLM2 and SLM4) displayed lower particle 
size than the others (SLM1 and SLM3). This 
could be attributed to disruption of crystal order 
by liquid lipid since crystalline lipid matrix 
produced a larger particle diameter than 
amorphous matrix [16]. On the other hand, where 
the lipophilic phase was which was composed of 
liquid oil (o/w emulsion) the formulation displayed 
the lowest droplet size, and this was due to high 
shear stirring.  
 
Difference in recrystalization behaviour and 
particle size of SLM did not significantly affect 
drug release rate. The highest release rate of 
LRT (154.65 mcg/cm2/h) was obtained from gel 
since the drug is not soluble in gel. Increase in 
lipophilicity of the vehicle led to a decrease in 
drug release rate of the conventional LRT 
formulations. The “n” values of Korsmeyer–
Peppas which is used for explaining release 
mechanisms indicate involvement of non-Fickian 
drug release, namely, super case II transport, 




Suitable SLM of LRT which could potentially be 
used for nasal application have been prepared. 
They demonstrated high drug entrapment and 
good particle size range and distribution for 
topical application as well as controlled release 
characteristics. However, further studies are 
required to ascertain their actual effectiveness for 
nasal delivery of LRT.  
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